BACKGROUND: New strains of methicillin-resistant Staphylococcus aureus (MRSA) which frequently carry the Panton-Valentine leukocidin (PVL) genes have been recognized to cause invasive infections in otherwise healthy children and adults. However, the epidemiology of PVL-positive MRSA infections has not been described in children or adults with cancer. PROCEDURE: The epidemiology of MRSA infections in patients with cancer was retrospectively studied from 2000 to 2007. Molecular typing was performed by polymerase chain reaction (PCR) for the detection of the PVL genes. Staphylococcus cassette chromosome (SCC) mec and spa typing was performed on all PVL-positive isolates. RESULTS: A total of 88 MRSA isolates from clinically distinct infectious episodes were collected from 88 patients with cancer during the 8-year study period. Infections were predominant in the skin and soft tissues (SSTI; P = 0.0003). PVL-positive isolates, bearing the type IV SCCmec element, encoding the gene for methicillin resistance, increased significantly during this period (P = 0.043) and comprised 35 of 88 (40%) MRSA isolates. Of these 35 isolates, 32 belonged to spa type 8 and were USA300 genotype. Patients infected with PVL-positive strains did not have more SSTI (P = 0.166) or bacteremia (P = 0.510) as compared to patients with PVL-negative strains. A greater percentage of PVL-positive isolates were susceptible to ciprofloxacin (P = 0.006). CONCLUSIONS: PVL-positive MRSA infections are not associated with a higher morbidity as compared to PVL-negative MRSA infections in children with cancer. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: New strains of methicillin-resistant Staphylococcus aureus (MRSA) which frequently carry the Panton-Valentine leukocidin (PVL) genes have been recognized to cause invasive infections in otherwise healthy children and adults. However, the epidemiology of PVL-positive MRSA infections has not been described in children or adults with cancer. PROCEDURE: The epidemiology of MRSA infections in patients with cancer was retrospectively studied from 2000 to 2007. Molecular typing was performed by polymerase chain reaction (PCR) for the detection of the PVL genes. Staphylococcus cassette chromosome (SCC) mec and spa typing was performed on all PVL-positive isolates. RESULTS: A total of 88 MRSA isolates from clinically distinct infectious episodes were collected from 88 patients with cancer during the 8-year study period. Infections were predominant in the skin and soft tissues (SSTI; P = 0.0003). PVL-positive isolates, bearing the type IV SCCmec element, encoding the gene for methicillin resistance, increased significantly during this period (P = 0.043) and comprised 35 of 88 (40%) MRSA isolates. Of these 35 isolates, 32 belonged to spa type 8 and were USA300 genotype. Patients infected with PVL-positive strains did not have more SSTI (P = 0.166) or bacteremia (P = 0.510) as compared to patients with PVL-negative strains. A greater percentage of PVL-positive isolates were susceptible to ciprofloxacin (P = 0.006). CONCLUSIONS: PVL-positive MRSA infections are not associated with a higher morbidity as compared to PVL-negative MRSA infections in children with cancer. (c) 2009 Wiley-Liss, Inc.
Authors: Keiko Okuma; Kozue Iwakawa; John D Turnidge; Warren B Grubb; Jan M Bell; Frances G O'Brien; Geoffrey W Coombs; John W Pearman; Fred C Tenover; Maria Kapi; Chuntima Tiensasitorn; Teruyo Ito; Keiichi Hiramatsu Journal: J Clin Microbiol Date: 2002-11 Impact factor: 5.948
Authors: Maria Labandeira-Rey; Florence Couzon; Sandrine Boisset; Eric L Brown; Michele Bes; Yvonne Benito; Elena M Barbu; Vanessa Vazquez; Magnus Höök; Jerome Etienne; François Vandenesch; M Gabriela Bowden Journal: Science Date: 2007-01-18 Impact factor: 47.728
Authors: Timothy S Naimi; Kathleen H LeDell; Kathryn Como-Sabetti; Stephanie M Borchardt; David J Boxrud; Jerome Etienne; Susan K Johnson; Francois Vandenesch; Scott Fridkin; Carol O'Boyle; Richard N Danila; Ruth Lynfield Journal: JAMA Date: 2003-12-10 Impact factor: 56.272
Authors: R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin Journal: JAMA Date: 2007-10-17 Impact factor: 56.272
Authors: Ashok Srinivasan; Steven E Seifried; Liang Zhu; Deo K Srivastava; Rosalie Perkins; Jerry L Shenep; Matthew J Bankowski; Randall T Hayden Journal: Pediatr Blood Cancer Date: 2010-09-09 Impact factor: 3.167
Authors: J-P Rasigade; S Trouillet-Assant; S Breurec; K Antri; G Lina; M Bes; A Tristan; C Badiou; M Bernelin; C Fall; N Ramdani-Bouguessa; J Etienne; F Vandenesch; F Laurent Journal: Eur J Clin Microbiol Infect Dis Date: 2015-01-10 Impact factor: 3.267